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Abstract
Background
Currently available treatments for secondary progressive multiple sclerosis(SPMS) have
limited efficacy and/or safety concerns. Adipose-mesenchymal derived stem cells(AdMSCs)
represent a promising option and can be readily obtained using minimally invasive
procedures.
Patients and methods
In this triple-blind, placebo-controlled study, cell samples were obtained from consenting
patients by lipectomy and subsequently expanded. Patients were randomized to a single
infusion of placebo, low-dose(1x106cells/kg) or high-dose(4x106cells/kg) autologous
AdMSC product and followed for 12 months. Safety was monitored recording adverse
events, laboratory parameters, vital signs and spirometry. Expanded disability status score
(EDSS), magnetic-resonance-imaging, and other measures of possible treatment effects
were also recorded.
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Results
Thirty-four patients underwent lipectomy for AdMSCs collection, were randomized and thirty
were infused (11 placebo, 10 low-dose and 9 high-dose); 4 randomized patients were not
infused because of karyotype abnormalities in the cell product. Only one serious adverse
event was observed in the treatment arms (urinary infection, considered not related to study
treatment). No other safety parameters showed changes. Measures of treatment effect
showed an inconclusive trend of efficacy.
Conclusion
Infusion of autologous AdMSCs is safe and feasible in patients with SPMS. Larger studies
and probably treatment at earlier phases would be needed to investigate the potential thera-
peutic benefit of this technique.
Introduction
There are two main forms of multiple sclerosis (MS): relapsing remitting MS (RRMS),
whose underlying pathophysiology is considered inflammatory, and secondary progressive
MS (SPMS), which develops from RRMS [1] A primary progressive form (PPMS) also exists
but is rarer 10–15% of cases of MS). In recent years, great progress has been made in the
treatment of RRMS, with the availability of a range of new drugs that target the inflamma-
tory component of the disease[2]. In the case of SPMS, whose pathological processes are
thought to involve neurodegeneration,[3] little progress has been made and few treatments
are authorized. Although interferon β is indicated for SPMS with disease activity (exacerba-
tions or magnetic resonance imaging new, enlarging or enhancing lesions), the evidence for
efficacy of this treatment is tenuous.[4] Mitoxantrone, in contrast, appears to have some
impact on the disease [5] but has problems with long-term toxicity (cardiotoxicity and leu-
kemia).[6] Ocrelizumab have recently been approved by the FDA for the treatment of
PPMS [7]. PPMS is part of a spectrum of overlapping MS phenotypes with different patho-
genesis. Thus, despite the highly debilitating nature of SPMS and the clear medical need,
there is currently no truly effective treatment available.Recently, stem cells have demon-
strated safety and a variable degree of efficacy in a diverse range of indications [8–17], but
they are approved just for transplantation of blood stem cells to treat diseases and condi-
tions of the blood and immune system, or to restore the blood system after treatments for
specific cancers; skin stem cells to grow skin grafts for patients with severe burns on very
large areas of the body and limbal stem-cell-based treatment to repair damage to the cornea.
As of now, no treatments using mesenchymal stem cells have been licensed. There are, how-
ever, some clinical trials investigating the safety and effectiveness of MSC treatments for
repairing bone or cartilage. Other trials are investigating whether mesenchymal stem cells
might help repair blood vessel damage linked to heart attacks or diseases such as critical
limb, help treat transplant rejection or autoimmune diseases are still under thorough inves-
tigation. In the case of MS, paracrine effects on central nervous system and the potential for
increased endogenous axonal and myelin repair processes may be of benefit.[18,19] Encour-
aged by endogenous CNS repair demonstrated by stem cells in animal models of MS,[20]
investigators aimed to test the effects of stem cells in humans [21] and a number of studies
with intrathecal and/or intravenous administration of bone-marrow derived mesenchymal
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stem cells (BM-MSCs) in patients with MS have been reported.[22–25] Of particular note
was an exploratory not blinded study of patients with SPMS involving visual pathways, in
which the treatment was found to be safe and evidence was reported of structural, func-
tional, and physiological improvement in visual endpoints. Particularly, the use of visual
evoked potentials as an outcome measure proved to be of a great usefulness detecting subtle
improvements, as the treatment demonstrated a decreased visual evoked response latency
(-133 ms, 95%CI-244 to -021; p = 0020).[26] Other studies have investigated both intra-
venous and intrathecal administration of BM-MSCs in patients with either MS or amyotro-
phic lateral sclerosis (ALS) [27], and RRMS patients,[28] showing that the procedures are
safe and some evidence of immunomodulatory effects.
Adipose-derived stem cells (AdMSCs) are another source of MSC, [29] with the advantage
that the samples for stem cell production can be taken with a minimally invasive lipectomy
procedure. With the exception of a report of 3 patients treated with stromal vascular fraction
(cells from unexpanded adipose samples) [30], and another two small studies [31,32] the
potential of adipose tissue as a source of stem cells has not been explored. The aim of the pres-
ent study was to assess the safety and feasibility of two different doses of AdMSCs administered
by intravenous infusion in patients with SPMS.
Methods
Design and patients
In this two-center (Hospital Regional Universitario de Ma´laga and Hospital Virgen Macarena
in Seville), phase I/II, placebo-controlled study, we randomized patients 1:1:1 to an intravenous
infusion of placebo or one of two dose-groups (1x106 cells/kg or 4x106 cells/kg). The study was
triple blinded; treating physician, patient and statisticians were unaware of treatment assign-
ment. The laboratory staff producing the AdMSC drug product or placebo had no direct contact
with the clinical staff. Randomization was performed at CABIMER with a random allocation
sequence using sequentially numbered containers stratified by treatment center.
To be eligible for the study, adult patients of either sex had to have a diagnosis of SPMS, with
an Expanded Disability Status Score (EDSS) between 5.5 and 9 and have failed previous thera-
pies and have activity or progression of the disease (relapse in the previous year or progression
of at least 0.5 points on the EDSS despite therapy). Patients were excluded if they had experi-
enced a relapse or had received steroid treatment in the month prior to inclusion. Patients posi-
tive for HIV, hepatitis B, or hepatitis C, history of malignant neoplasms, participation in an
interventional trial in the previous 3 months, contraindications for magnetic resonance imaging
(MRI), history of liver, kidney, cardiac, or psychiatric disease that may have impacted the study
procedures were also excluded. Finally, it had to be possible to collect 30 g of adipose tissue for
the AdMSC preparation.
After infusion at the baseline visit, patients entered 1 year follow-up (with visits scheduled at
30 days, 6 months and 12 months after the baseline visit). Prior to any study procedures, full
informed consent was obtained in writing from all participants. The study was approved by the
corresponding ethics committee (Comite´ Coordinador de E´tica de la Investigacio´n Biome´dica
de Andalucı´a) and registered with the clinicaltrials.gov clinical registry (ID, NCT01056471)
prior to initiation. The sponsor was the Andalusian Initiative for Advanced Therapies, sup-
ported by the Andalusian Health and Progress Foundation.
Treatment protocol
AdMSC preparation. Abdominal subcutaneous adipose tissue from MS patients was
obtained by lipectomy at the participating centers. The fresh adipose tissue was transported to
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the Good Manufacturing Practice (GMP) facility (Centro Andaluz de Biologı´a Molecular y
Medicina Regenerativa [CABIMER], Seville, Spain) at 2–20˚C within 12 hours of collection.
Adipose tissue was washed at least three times with phosphate buffered saline (PBS) supple-
mented with a Penicillin-streptomycin mixture (Sigma-Aldrich, St Louis,MO,USA). The adi-
pose tissue was minced and was enzymatically digested with an equal volume of 0.2%
collagenase type I (Sigma-Aldrich) solution for 1 hour at 37˚C with shaking. Cells were then
separated by centrifugation at 600×g for 10 min after addition of 10% fetal bovine serum (FBS,
SAFCBiosciences,Lenexa,Kansas,USA). The semisolid phase and the pellets were passed
through a 100 μm cell-strainer to remove debris and cell clumps. Subsequently, the stromal
vascular fraction (SVF) cells underwent a second centrifugation, and the isolated cells were re-
suspended in a culture medium (Dulbecco’s modified Eagle’s medium[DMEM,Sigma-
Aldrich]) supplemented with 10%FBS and 2%L-alanyl-L-glutamine (Sigma-Aldrich) for cell
count and assessment of viability.
After adjusting the cell seeding concentration, cells were plated into polystyrene cell culture
flasks and incubated at 37˚C in humidified 5%CO2 atmosphere. After 24–72 hours of incuba-
tion, the medium was changed and non-adherent cells were removed. For AdMSC cultures, a
complete change of medium every 2–3 days until reaching 80% confluence was applied. The
AdMSCs were then washed with PBS and treated with 0.05% trypsin-ethylenediaminetetraace-
tic acid(EDTA)(Invitrogen) for 15 minutes to detach them from the surface of the culture flask
and harvested with culture medium. The resulting suspension was re-plated in new cell culture
flasks. AdMSC expansion proceeded this way until reaching the dose level to which the patient
had been assigned (1x106cells/kg or 4x106cells/kg).
The cells were then harvested with basal medium after the treatment with trypsin-EDTA,
centrifuged and counted in a Neubauer chamber. After counting, the AdMSCs were washed
and resuspended in Ringer’s lactate supplemented with human serum albumin and glucose at
the appropriate concentration, and then packaged in 50 mL-syringes with female luer-lock caps.
The finished product was released after meeting the following quality controls: immuno-
phenotype (>90% positivity for CD90,CD73,CD105,CD13 and CD29, and<10%positivity for
CD14/CD20/CD34/CD45/CD31 and HLA class II), negativity for mycoplasms, negativity for
endotoxins, and no numeric or structural karyotype abnormalities. Results from the sterility
test were obtained prior to infusion and 14 days after the release of the finished product. The
placebo product consisted of Ringer’s lactate packaged in identical opaque 50 mL-syringes.
Administration. The AdMSCs were administered intravenously through a peripheral
venous catheter over 2 hours, using an infusion pump, mounted on a laboratory shaker to
avoid aggregation of the cells in the syringe. The speed of the infusion, number of cells infused
per minute, was calculated to be similar to the habitual rate of transfusion of red cells. During
all the procedures the blinding was assured by the appropriate measures (dark, opaque syrin-
ges and tubes were used). After infusion, patients remained in the clinic for 24 hours to moni-
tor for possible adverse events (AEs).
Exhaustive data about the adequate dosing of AdMSCs intravenously administered in
human treatment is lacking, so taking into account the existing literature [8–32], we estimated
that the ideal number of cells to administer intravenously to our MS patients would be between
107–1010.
Outcome measures
Neurological assessments were performed by experienced neurologists at the participating
centers. Safety was assessed primarily by monitoring for AEs and standard laboratory mea-
sures. Vital signs and spirometric parameters were also monitored. Possible treatment effects
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were assessed by changes in baseline, 6 and 12 months after infusion: clinical variables (num-
ber of exacerbations, EDSS), immunologic assessments, analysis of cerebrospinal fluid (CSF),
MRI (T2-weighted lesions, T1 lesions, T1 gadolinium-enhanced lesions, volume, and magneti-
zation transfer ratio-MTR), evoked potentials (EP) (visual-VEP, acoustic-BAEP, somatosen-
sory-SEP and motor-MEP), optical coherence tomography (OCT) of the retina (retinal nerve
fiber layer- RNFL), cognition measured with Paced Auditory Serial Addition Test (PASAT)
and quality-of-life by questionnaire SF-36, EuroqoL-5D and MusiQoL.
Statistical analysis
Given that this was an exploratory study and that previous efficacy and safety studies with
AdMSCs were lacking, no formal sample size calculations were performed. In order to provide
an indication of safety and dose-effect and to support future larger efficacy studies, 30 evalu-
able patients were considered sufficient.
For the purposes of this study, the safety analysis population was defined as all patients who
underwent a lipectomy procedure. The intention-to-treat population comprised all patients
who were randomized and received an infusion and the per protocol population comprised
patients which accomplished the inclusion criteria with at least 1 post baseline visit.
Descriptive statistics were calculated for all outcome measures (means and standard devia-
tions, standard errors, medians and interquartile ranges, or numbers and percentages, as
appropriate). Baseline clinical and paraclinical data were compared to 12 months after treat-
ment data using Student´s t test. The treatment effect of the two doses of treatment vs placebo
was analyzed by non-parametric tests (Kruskal-Wallis test) and ANOVA of repeated measures
for the clinical and paraclinical test performed at baseline, and 12 months.
Results
Study patients
The patient disposition is shown in Fig 1. 34 patients were randomized following lipectomy.
Four randomized patients (3 assigned to the high dose group and 1 to the low dose group)
were not infused because of karyotype anomalies in the cell product. There were no clinical
differences of this group of 4 patients (age, EDSS or disease duration) when compared with the
final infused group (data not shown). Thus 30 patients were infused and constitute the inten-
tion-to-treat population (ITT, Table 1). Of these 30 patients, 29 had at least 1 post-baseline
assessment and were considered the per-protocol population. One patient had choking and
bronchial aspiration while being fed 2 days after the infusion and died subsequently. All 29
patients in the per-protocol population completed 12 months follow-up. Analysis reported in
this paper have been performed on all patients having had a procedure of lipectomy for tolera-
bility and safety, according to predefined statistical analysis (Table 2) and on the ITT popula-
tion for the efficacy variables.
The patients baseline characteristics are summarized in Table 1. 70% were women and ages
ranged from 31 to 61 years. The disease duration ranged from 8 to 38 years. Most patients (25/
30 [83%]) had monofocal symptoms at presentation and the baseline EDSS ranged from 6.0 to
9.0. Only 2 patients (7%) had experienced more than 1 relapse in the 2 years prior to enrol-
ment. The mean number of Gd-enhanced T1 lesions was higher in the high-dose group (2.0
±2.88 SD3.56±5.39) compared to the other groups, although this difference was driven by an
outlier patient with 16 lesions (compared to maxima of 5 and 3 in the placebo and low-dose
groups). Otherwise, the number of T2 lesions was not statistically different between groups.
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Safety results
Two patients in the placebo group, died during the study: one patient had choking and bron-
chial aspiration while being fed 2 days after the infusion and one patient had a respiratory
infection nine months after infusion. They were women of 31 and 43 years old, with an EDSS
at the beginning of the clinical trial of 9 and 8,5 and with 13 years of evolution of the disease in
both cases.
A total of 70 AEs were reported during the trial period in 22 patients (67%). The most fre-
quently reported individual AEs were urinary infection, respiratory infection and anemia
(Table 2). Four serious AEs were reported (2 of these resulted in death, as described above).
None of these serious AEs were considered related to treatment by the investigators and only 1
(urinary infection in a patient who already had a urinary infection on inclusion) occurred in
an active treatment group (high-dose group).
No significant changes from baseline were observed for mean vital signs, spirometry or lab-
oratory values, except for a significant decrease in cholesterol and creatinine in the low-dose
group and a decrease in lymphocytes counts in the high-dose group, although the mean values
remained within normal reference ranges.
Fig 1. Patient disposition. Low dose = 1x106 AdMSCs/Kg; High dose = 4 x 106 AdMSCs/Kg.
https://doi.org/10.1371/journal.pone.0195891.g001
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Treatment effects
Outcomes in treatment effects variables after 12 months of treatment are shown in Table 3. No
variable showed statistically significant differences in repetitive measures neither by ANOVA
(pFisher—p.F) nor by Kruskal-Wallis (p.KW) tests.
The mean EDSS score did not show statistically significant variations over the course of the
study (baseline EDSS for placebo, low-dose and high-dose groups were 7.64±0.314, 7.50±0.24,
and 7.78±0.16 SE at baseline, compared to 7.55±0.35, 7.75±0.24, and 8.06±0.41 SE at 12
months p.F = 0,57; p.kW = 0,20). Individual EDSS changes were not significant as well. (See
Table 1. Baseline disease characteristics.
Placebo (n = 11) Low Dose (n = 10) High Dose (n = 9) Overall (n = 30)
Demographic Characteristics
Sex
Male 3(27%) 4 (40%) 2 (22%) 9 (30%)
Female 8 (73%) 6 (60%) 7 (78%) 21 (70%)
Age (years) 46.3±8.9 44.8±8.0 47.8±9.7
Disease Characteristics
EDSS 7.64±0.98 7.50±0.71 7.78±0.44
Relapses
1 in past 2 years 3 (27%) 5 (50%) 1 (11%) 9 (30%)
2 in past 2 years 0 0 2 (22%) 2 (7%)
1 in past year 2 (18%) 3 (30%) 3 (30%) 8 (27%)
Disease duration (years) 18.9±7.3 15.4±6.1 18.7±8.7
MRI
Gd-enhanced T1 lesions 0.82±1.17 0.70±1.57 2.0±2.88
T2 lesions 159.0±78.4 152.4±49.9 140.75±35.3
EDSS: expanded disability status scale; MRI: magnetic resonance imaging. Data presented as mean±SD or count (%)
https://doi.org/10.1371/journal.pone.0195891.t001
Table 2. Adverse events during the trial.
Placebo (n = 11) Low Dose (n = 11) High Dose (n = 12) Active Treatment (n = 23)
AEs
Patients with AEs 8 (73%) 5 (45%) 9 (75%) 14 (61%)
Number of AEs 27 8 35 43
Most frequent individual AEs
Patients with urinary infection 3 (27%) 2 (18%) 1 (8%) 3 (13%)
Patients with respiratory infection 3 (27%) 0 1 (8%) 1 (4%)
Patients with anemia 2 (18%) 1 (9%) 2 (17%) 3 (13%)
Causality of AEs
Unlikely 27 8 32 40
Likely 0 0 2 2
Possible 0 0 1 1
SAEs
Patients with SAEs 3 (27%)a 0 1 (8%) 1 (4%)b
a Choking, respiratory infection, urinary infection
b Urinary infection
AE: adverse event; SAE: serious adverse event
Data presented as number (%).
https://doi.org/10.1371/journal.pone.0195891.t002
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Supplementary Files S2 File—EDSS individual changes and S9 File—Changes in treatment
effects variables after 12 months of treatment-complete data)
Baseline MRI data of the three groups were similar, with no significant differences. Non sta-
tistically significant post-baseline changes were observed in low and high dose group for num-
ber of active lesions in the Gd-enhanced T1 scans (although, as mentioned above, at baseline,
an outlier patient in the high dose group had 16 active lesions). A decrease in MRI non nor-
malized cerebral volume in low dose group and in MTR was observed, being significant in
paired t-test between baseline and the 12 months outcome, although there were no differences
Table 3. Changes in treatment effects variables after 12 months of treatment.
Placebo Low dose High dose
Variable Baseline Outcome (12
months)
Baseline Outcome (12
months)
Baseline Outcome (12
months)
EDSS 7.64±0.31 -0.09±0.17 7.50±0.24 0.25±0.09 7.78±0.16 0.28±0.52
MRI MRI T1 number of lesions 62.18±7.18 1.22±0.68 46.40±9.45 0.20±0.81 40.56±6.70 -0.67±0.71
MRI T1 area (cm2) 197.17
±71.85
0.34±1.08 111.51
±35.26
7.74±5.17 94.78±34.99 -0.93±1.43
MRI T1GAD number of lesions 0.82±0.37 0.50±0.63 0.70±0.52 -0.10±0.25 2.00±1.09 -0.75±0.72
MRI T1GAD area (cm2) 0.01±0.00 0.00±0.01 0.01±0.01 0.01±0.02 0.02±0.01 -0.01±0.01
MRI T2 number of lesions 159.0±24.79 -1.30±2.79 152.40
±16.62
2.50±2.67 140.75
±13.34
2.50±1.82
MRI T2 area (cm2) 440.7±130.1 16.4±9.7 298.9±67.0 8.66±5.16 296.70
±57.61
23.78±19.49
MRI normalized cerebral volume (cm3) 1420.6±24.2 -5.1±7.1 1483.7±26.7 -23.5±11.8 1449.2±32.6 -11.4±19.8
MRI non normalized cerebral volume
(cm3)
1062.9
±37.94
-11.8±7.3 1112.7±28.9 -29.8±11.9 1036.8±58.5 5.7±24.1
MTR 18.1±0.51 -1.21±0.62 18.3±0.49 -2.00±0.62 19.06±0.78 -2.0±0.9
Evoked VEP p100 Latency (ms) 134.45
±11.91
18.00±15.21 164.82
±12.11
-0.58±13.63 156.49±9.63 -13.48±14.77
potentials VEP amplitude (µV) 4.02±0.88 -0.71±0.71 3.26±0.78 -0.44±0.74 4.31±1.30 -2.41±0.78
BAEP I-V Interval (ms) 3.86±0.12 0.03±0.17 4.46±0.19 -0.24±0.25 4.26±0.15 0.04±0.15
BAEP V/I amplitude 37.62±14.54 3.26±11.26 38.36±16.82 -5.69±17.83 25.50±12.49 -16.06±15.70
Median nerve SEP (N13-N20) (ms) 12.82±1.14 -0.76±1.21 24.71±10.50 -10.49±10.64 17.57±5.85 -6.76±6.88
Tibial nerve SEP (N22-P39) (ms) 43.62±2.64 -8.42±2.56 44.38±1.61 -8.76±2.88 45.74±1.60 -11.24±2.41
MEP superior CCT (ms) 48.25±11.26 -20.11±10.02 44.48±12.70 -16.15±10.55 51.76±15.61 -30.90±16.72
MEP inferior CCT (ms) 72.70±5.73 -28.68±6.96 75.92±6.30 -35.18±4.82 75.07±7.25 -27.64±9.76
P300 Latency (ms) 380.14
±32.04
42.24±46.39 332.20
±21.48
22.13±11.44 373.92
±21.61
-4.22±12.93
EPAS 24.27±1.36 -0.10±1.57 23.70±1.99 1.90±1.07 22.78±1.32 1.43±1.00
OCT Optic coherence tomography RNFL
(μm)
70.95±6.11 -1.06±2.97 72.00±5.23 -1.94±3.56 67.56±5.27 -1.79±2.19
Cognition PASAT 36.50±8.09 4.17±1.86 30.17±4.37 -2.60±2.41 31.00±7.10 0.25±3.24
and QoL QoL (EQ5D) 45.91±8.27 -4.44±7.78 47.03±9.25 -2.53±6.95 50.00±7.76 1.88±6.62
EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging; GAD: gadolinium enhanced; MTR: magnetization transfer ratio; VEP: visual evoked
potential; BAEP: brainstem acoustic evoked potential; SEP: somatosensory evoked potential; MEP: motor evoked potential; CCT: central conduction time; EPAS:
evoked potential abnormality score; OCT: Optic coherence tomography; RNFL: retinal nerve fiber layer; PASAT: Paced Auditory Serial Addition Test; EQ5D: EuroQol-
5D; ms: milliseconds; μV: microvolts; μm: micrometer.
Data presented at baseline and after 12 months (change) as mean±SE
P0,05 significative change (paired Student’s t test for changes within groups). No significant differences between groups were detected by Fisher‘s -pF- and Kruskal-
Wallis -pKW- tests.
https://doi.org/10.1371/journal.pone.0195891.t003
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between the three groups when compared between them (MRI non normalized cerebral vol-
ume: p.F = 0,23; p.kW = 0,28; MTR: p.F = 0,60; p.kW = 0,50).
Evoked potentials showed no significant baseline difference between groups. We found
some non-statistically significant differences between the placebo and treatment groups for
the evoked potentials parameters after 12 months of treatment. Tibial SEP central conduction
time (N22-P39) and the MEP central conduction time for the legs, demonstrated statistically
significant diminishing latencies over time in placebo and the two treatment groups, but these
differences were not statistically significant comparing placebo and both treatment groups.
Visual evoked potential-VEP and median nerve SEP (N13-N20) also showed a trend of stabili-
zation or amelioration of latencies over time in treatment groups, although these differences
didn´t reach statistically significance over the time, as well as between groups;(p.F = 0,59; p.
kW = 0,89).
No significant changes from baseline were observed for the analysis of cerebral spinal fluid,
OCT measurements, cognition or quality of life questionnaires.
The immunological parameters of this study will be published separately.
Discussion
In this phase I/II proof-of-concept trial, intravenous infusion of AdMSCs was safe over the
12-month follow-up period. The pattern of AEs reported was one that would be expected from
the underlying disease. No related serious AEs occurred and laboratory tests, vital signs, and
spirometry did not identify any safety issues.
The safety findings from this study are in line with previous reports of stem cells in patients
with SPMS, although these studies were performed with BM-MSC.[22–28] In the study
reported by Connick et al,[26] 10 patients were intravenously infused with BM-MSCs, with
the only AEs of note being 2 cases of infections and 2 skin reactions over up to 10.2 months of
follow-up. In another study, Karussis et al [27] treated 15 patients with MS and 19 with ALS
either intrathecally (34 patients) or intravenously (14 patients), the overall safety profile was
good, with no major events reported during up to 25 months of follow-up, except for a case of
meningeal irritation and aseptic meningitis in 1 patient. In the randomized, double-blind, pla-
cebo-controlled, crossover phase II clinical trial by Llufriu [28]28, 9 RRMS patients were
treated and no serious adverse events were identified after 12 months of follow-up.
The most frequently reported individual AEs in this clinical trial were urinary infections,
respiratory infections and anemia. None of these serious AEs were considered related to treat-
ment by the investigators and only 1 (urinary infection in a patient who already had a urinary
infection on inclusion) occurred in an active treatment group (high-dose group). Two patients
in the placebo group, died during the study: one patient had choking and bronchial aspiration
while being fed 2 days after the infusion and one patient had a respiratory infection nine
months after infusion. Transplantation of stem cells can increase the risk of neoplasms. [33]
No neoplasms were reported during our study after one year postinfusion. Animal studies
with AdMSCs and MSC in humans have not detected any oncogenic potential.[34–36]
Evidence for a treatment effect was detected in the aforementioned studies with BM-MSCs.
Connick et al,[26] reported evidence of structural, functional and physiological improvement
after treatment in some visual endpoints. Karussis et al,[27]reported almost immediate immu-
nomodulatory effects and a significant reduction in EDSS score in MS patients (from mean
±SD 6.7± 1.0 before the intervention to 5.9±1.6 after the intervention). Llufriu [28], showed a
trend but not significant treatment differences in the secondary efficacy endpoints.
Although data on possible markers of treatment effects were collected, our study with
AdMSCs was not powered to demonstrate such effects and, unsurprisingly, no clear effects
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were detected. In the MRI studies, non statistically significant post-baseline changes were
observed in the low and high dose group for number of active lesions in the Gd-enhanced T1.
EP measures showed a statistically significant trend of efficacy by the reduction of latencies of
somatosensory central conduction time for the arms, and some of the measured EP parame-
ters: VEP latency, the tibial SEP central conduction time for the legs (N22-P39) and the MEP
central conduction time for the arms and legs, demonstrated diminishing latencies over time,
but these differences were not statistically significant with placebo. In clinical trials involving
patients in advanced phases of MS, when the neurodegenerative phase of the disease is more
prominent, dramatic effects are not to be expected, and there are no gold standard measures of
neurodegeneration, we should look for measures that are able to detect even minimal but
objective positive changes like evoked potentials have shown in other clinical trials [25] and in
this clinical trial.
We have to note that the baseline mean EDSS score of our patients was greater than 7.5
whereas the patients included in the study by Connick et al [26,37] had a mean baseline EDSS
of 6.1, implying that the patients in our study had more severe disease and that the baseline
MRI, evoked potentials and OCT measures showed very much affected baseline parameters
(very high number of baseline lesions in MRI, not recordable or very slow EP and very thin
RNFL measured with OCT). This “ceiling effect” due to a severe disease is a well know bias in
comparing this type of measures. when variance in an independent variable is not well mea-
sured or estimated above a certain level, and it impairs the ability of investigators to determine
the central tendency of the data and differences between groups. We are afraid that this is the
case of our possible markers of treatment.
Although several reports have used BM-MSCs,[22–26] very few studies have used expanded
AdMSCs in patients with MS [31,32]. In view of the lack of robust data on treatment effects,
we are unable to make affirmations about the relative merits of AdMSCs versus BM-MSCs. In
principle, both are pluripotent stem cells that are able to undergo neural differentiation,[38]
but their immunologic phenotypes do differ,[39] so their immunomodulatory properties may
also vary.
Possible mechanisms of action of MSCs in SPMS include neuroprotection through para-
crine modifications of the CNS microenvironment and increased endogenous axonal and
myelin repair.[19,40]
From a procedural point of view, AdMSCs offer the potential advantage that the lipectomy
or liposuction procedures, which we know now can be used alternatively, to obtain the cell
sample are less invasive than bone marrow aspiration [29], and offer an alternative for the
obtainment of the MSCs.
In conclusion, the present study demonstrates that infusion of AdMSCs is a safe and feasi-
ble procedure in patients with SPMS. Although the study was not powered to determine theef-
ficacy, some hint of efficacy was observed by the use of MRI and evoked potentials. Larger
studies would be needed to investigate the potential therapeutic benefit of the technique.
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